Loading...
Comparison of vilanterol, a novel long-acting beta(2) agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids
BACKGROUND: Current maintenance therapies for asthma require twice-daily dosing. Vilanterol (VI) is a novel long-acting beta(2) agonist, under development in combination with fluticasone furoate, a new inhaled corticosteroid (ICS). Findings from a previous 4-week study suggested that VI has inherent...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4055937/ https://ncbi.nlm.nih.gov/pubmed/24928338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-5751-13-9 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|